TY - JOUR AU - DeFronzo, R. A. PY - 2009 DA - 2009// TI - From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus JO - Diabetes VL - 58 UR - https://doi.org/10.2337/db09-9028 DO - 10.2337/db09-9028 ID - DeFronzo2009 ER - TY - JOUR AU - Holst, J. J. PY - 1997 DA - 1997// JO - Enteroglucagon Ann Rev Physiol VL - 59 UR - https://doi.org/10.1146/annurev.physiol.59.1.257 DO - 10.1146/annurev.physiol.59.1.257 ID - Holst1997 ER - TY - JOUR AU - Nauck, M. A. AU - Stockmann, F. AU - Ebert, R. AU - Creutzfeldt, W. PY - 1986 DA - 1986// TI - Reduced incretin effect in type 2 (non-insulin dependent) diabetes JO - Diabetologia VL - 29 UR - https://doi.org/10.1007/BF02427280 DO - 10.1007/BF02427280 ID - Nauck1986 ER - TY - JOUR AU - Nauck, M. A. AU - Heimesaat, M. M. AU - Orskov, C. AU - Holst, J. J. AU - Ebert, R. AU - Creutzfeldt, W. PY - 1993 DA - 1993// TI - Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus JO - J Clin Invest VL - 91 UR - https://doi.org/10.1172/JCI116186 DO - 10.1172/JCI116186 ID - Nauck1993 ER - TY - JOUR AU - Vilsboll, T. AU - Agerso, H. AU - Krarup, T. AU - Holst, J. J. PY - 2003 DA - 2003// TI - Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects JO - J Clin Endo Metab VL - 88 UR - https://doi.org/10.1210/jc.2002-021053 DO - 10.1210/jc.2002-021053 ID - Vilsboll2003 ER - TY - JOUR AU - Neumiller, J. J. AU - Wood, L. AU - Campbell, R. K. PY - 2010 DA - 2010// TI - Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus JO - Pharmacotherapy VL - 30 UR - https://doi.org/10.1592/phco.30.5.463 DO - 10.1592/phco.30.5.463 ID - Neumiller2010 ER - TY - JOUR AU - Deacon, C. F. AU - Holst, J. J. PY - 2009 DA - 2009// TI - Saxagliptin: a new dipeptidylpeptidase-4 inhibitor for the treatment of type 2 diabetes JO - Adv Ther VL - 26 UR - https://doi.org/10.1007/s12325-009-0030-9 DO - 10.1007/s12325-009-0030-9 ID - Deacon2009 ER - TY - JOUR AU - Zerilli, T. AU - Pyon, E. Y. PY - 2007 DA - 2007// TI - Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus JO - Clin Ther VL - 29 UR - https://doi.org/10.1016/j.clinthera.2007.12.034 DO - 10.1016/j.clinthera.2007.12.034 ID - Zerilli2007 ER - TY - JOUR AU - Mu, J. AU - Petrov, A. AU - Eiermann, G. J. AU - Woods, J. AU - Zhou, Y. -. P. AU - Li, Z. AU - Zycband, W. AU - Feng, Y. AU - Zhu, L. AU - Roy, R. S. AU - Howard, A. D. AU - Li, C. AU - Thornberry, N. A. AU - Zhang, B. B. PY - 2009 DA - 2009// TI - Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes JO - Eur J Pharmacol VL - 623 UR - https://doi.org/10.1016/j.ejphar.2009.09.027 DO - 10.1016/j.ejphar.2009.09.027 ID - Mu2009 ER - TY - JOUR AU - Copeland, R. A. AU - Harpel, M. R. AU - Tummino, P. J. PY - 2007 DA - 2007// TI - Targeting enzyme inhibitors in drug discovery JO - Expert Opin Ther Targets VL - 11 UR - https://doi.org/10.1517/14728222.11.7.967 DO - 10.1517/14728222.11.7.967 ID - Copeland2007 ER - TY - JOUR AU - Morrison, J. F. AU - Walsh, C. T. PY - 1988 DA - 1988// TI - The behavior and significance of slow-binding enzyme inhibitors JO - Adv Enzymol VL - 61 ID - Morrison1988 ER - TY - JOUR AU - Hughes, T. E. AU - Mone, M. D. AU - Russell, M. E. AU - Weldon, S. C. AU - Villhauer, E. B. PY - 1999 DA - 1999// TI - NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV JO - Biochemistry VL - 38 UR - https://doi.org/10.1021/bi990852f DO - 10.1021/bi990852f ID - Hughes1999 ER - TY - JOUR AU - Augeri, D. J. AU - Robl, J. A. AU - Betebenner, D. A. AU - Magnin, D. R. AU - Khanna, A. AU - Robertson, J. G. AU - Wang, A. AU - Simpkins, L. M. AU - Taunk, P. AU - Huang, Q. PY - 2005 DA - 2005// TI - Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes JO - J Med Chem VL - 48 UR - https://doi.org/10.1021/jm050261p DO - 10.1021/jm050261p ID - Augeri2005 ER - TY - JOUR AU - Thomas, L. AU - Eckhardt, M. AU - Langkopf, E. AU - Tadayyon, M. AU - Himmelsbach, F. AU - Mark, M. PY - 2008 DA - 2008// TI - (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 Inhibitors JO - J Pharm Exp Thera VL - 325 UR - https://doi.org/10.1124/jpet.107.135723 DO - 10.1124/jpet.107.135723 ID - Thomas2008 ER - TY - JOUR AU - Copeland, R. A. AU - Pompliano, D. L. AU - Meek, T. D. PY - 2006 DA - 2006// TI - Drug-target residence time and its implications for lead optimization JO - Nat Rev Drug Disc VL - 5 UR - https://doi.org/10.1038/nrd2082 DO - 10.1038/nrd2082 ID - Copeland2006 ER - TY - JOUR AU - De Leon, D. D. AU - Crutchlow, M. F. AU - Ham, J. -. Y. N. AU - Stoffers, D. A. PY - 2006 DA - 2006// TI - Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus JO - Int J Biochem Cell Biol VL - 38 UR - https://doi.org/10.1016/j.biocel.2005.07.011 DO - 10.1016/j.biocel.2005.07.011 ID - De Leon2006 ER - TY - JOUR AU - Kirby, M. AU - Yu, D. M. T. AU - O' Connor, S. P. AU - Gorrell, M. D. PY - 2010 DA - 2010// TI - Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition JO - Clin Sci VL - 118 UR - https://doi.org/10.1042/CS20090047 DO - 10.1042/CS20090047 ID - Kirby2010 ER - TY - JOUR AU - Fura, A. AU - Khanna, A. AU - Vyas, V. AU - Koplowitz, B. AU - Chang, S. -. Y. AU - Caporuscio, C. AU - Boulton, D. W. AU - Christopher, L. W. AU - Chadwick, K. D. AU - Hamann, L. G. AU - Humphreys, W. G. AU - Kirby, M. PY - 2009 DA - 2009// TI - Pharmacokinetics of the Dipeptidyl Peptidase 4 Inhibitor Saxagliptin in Rats, Dogs, and Monkeys and Clinical Projections JO - Drug Metab Disp VL - 37 UR - https://doi.org/10.1124/dmd.108.026088 DO - 10.1124/dmd.108.026088 ID - Fura2009 ER - TY - JOUR AU - Deacon, C. F. AU - Holst, J. J. PY - 2010 DA - 2010// TI - Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes JO - Expert Opin Investig Drug VL - 19 UR - https://doi.org/10.1517/13543780903463862 DO - 10.1517/13543780903463862 ID - Deacon2010 ER - TY - JOUR AU - Kim, Y. B. AU - Kopcho, L. M. AU - Kirby, M. S. AU - Hamann, L. G. AU - Weigelt, C. A. AU - Metzler, W. J. AU - Marcinkeviciene, J. PY - 2006 DA - 2006// TI - Mechanism of Gly-Pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118) JO - Arch Biochem Biophys VL - 445 UR - https://doi.org/10.1016/j.abb.2005.11.010 DO - 10.1016/j.abb.2005.11.010 ID - Kim2006 ER - TY - JOUR AU - Ajami, K. AU - Pitman, M. R. AU - Wilson, C. H. AU - Park, J. AU - Menz, R. I. AU - Starr, A. E. AU - Cox, J. H. AU - Abbott, C. A. AU - Overall, C. M. AU - Gorrell, M. D. PY - 2008 DA - 2008// TI - Stromal cell-derived factors 1a and 1b, inflammatory protein-10 and interferon-inducible T cell chemo-attractant are novel substrates of dipeptidyl peptidase 8 JO - FEBS Letters VL - 582 UR - https://doi.org/10.1016/j.febslet.2008.02.005 DO - 10.1016/j.febslet.2008.02.005 ID - Ajami2008 ER - TY - JOUR AU - Krishna, R. AU - Herman, G. AU - Wagner, J. A. PY - 2008 DA - 2008// TI - Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes JO - AAPS J VL - 10 UR - https://doi.org/10.1208/s12248-008-9041-8 DO - 10.1208/s12248-008-9041-8 ID - Krishna2008 ER - TY - JOUR AU - Boulton, D. W. AU - Geraldes, M. PY - 2007 DA - 2007// TI - Safety, tolerability, pharmacokinetics and pharmacodynamics of once-daily oral doses of saxagliptin for 2 weeks in type 2 diabetics and healthy subjects JO - Diabetes VL - 56 UR - https://doi.org/10.2337/db06-0310 DO - 10.2337/db06-0310 ID - Boulton2007 ER - TY - JOUR AU - Bergman, A. J. AU - Stevens, C. AU - Zhou, Y. AU - Yi, B. AU - Laethem, M. AU - De Smet, M. AU - Snyder, K. AU - Hilliard, D. AU - Tanaka, W. AU - Zeng, W. PY - 2006 DA - 2006// TI - Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a didpeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers JO - Clin Ther VL - 28 UR - https://doi.org/10.1016/j.clinthera.2006.01.015 DO - 10.1016/j.clinthera.2006.01.015 ID - Bergman2006 ER - TY - JOUR AU - He, Y. L. AU - Sabo, R. AU - Campestrini, J. AU - Wang, Y. AU - Riviere, G. J. AU - Nielsen, J. C. AU - Rosenberg, M. AU - Ligueros-Saylan, M. AU - Howard, D. AU - Dole, W. P. PY - 2008 DA - 2008// TI - The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers JO - Br J Clin Pharmacol VL - 65 UR - https://doi.org/10.1111/j.1365-2125.2007.03031.x DO - 10.1111/j.1365-2125.2007.03031.x ID - He2008 ER - TY - JOUR AU - Holst, J. J. AU - Deacon, C. F. PY - 2005 DA - 2005// TI - Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors JO - Diabetologia VL - 48 UR - https://doi.org/10.1007/s00125-005-1705-7 DO - 10.1007/s00125-005-1705-7 ID - Holst2005 ER - TY - JOUR AU - Villhauer, E. B. AU - Brinkman, J. A. AU - Naderi, G. B. AU - Burkey, B. F. AU - Dunning, B. E. AU - Prasad, K. AU - Mangold, B. L. AU - Russell, M. E. AU - Hughes, T. E. PY - 2003 DA - 2003// TI - 1-[[(3-hydroxy-1-adamantyl)amino] acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties JO - J Med Chem VL - 46 UR - https://doi.org/10.1021/jm030091l DO - 10.1021/jm030091l ID - Villhauer2003 ER - TY - JOUR AU - Kim, D. AU - Wang, L. AU - Beconi, M. AU - Eiermann, G. J. AU - Fisher, M. H. AU - He, H. AU - Hickey, G. J. AU - Kowalchick, J. E. AU - Leiting, B. AU - Lyons, K. PY - 2005 DA - 2005// TI - (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8 H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes JO - J Med Chem VL - 48 UR - https://doi.org/10.1021/jm0493156 DO - 10.1021/jm0493156 ID - Kim2005 ER -